Second US court declares Pfizer's Zoloft not liable for congenital heart defect

12 June 2015
medical_legal_law_big

A state court jury in the USA has ruled that pharma giant Pfizer (NYSE: PFE) was not responsible for the birth defects in a child whose mother used Zoloft (sertraline) during pregnancy.

The jury rejected claims by the plaintiff that Pfizer had neglected to properly disclose the risk of birth defects associated with the antidepressant. This follows a state court decision in April where the St Louis court also determined Pfizer was not liable.

This is just one of more than 1000 cases pending in state and federal courts in the USA. The plaintiff is seeking $2.4 million in compensation and argues that her daughter’s heart abnormalities were caused by the use of Zoloft in pregnancy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical